FH-006

DRUG2 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based ChemotherapyMalignant Solid Tumor

Phase 1

Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors

RecruitingNCT06735144

Jiangsu HengRui Medicine Co., Ltd.Malignant Solid Tumor

Start: 2024-12-23End: 2027-12-31Target: 200Updated: 2025-12-05

Phase 3

FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.

Not yet recruitingNCT07790380

Jiangsu HengRui Medicine Co., Ltd.Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy

Start: 2026-10-10End: 2029-06-30Target: 480Updated: 2026-08-27